{
    "clinical_study": {
        "@rank": "13474", 
        "arm_group": [
            {
                "arm_group_label": "Glycerin group (GG)", 
                "arm_group_type": "Active Comparator", 
                "description": "Glycerin group \"GG\" will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
            }, 
            {
                "arm_group_label": "Rectal stimulation group (SG)", 
                "arm_group_type": "Active Comparator", 
                "description": "Rectal stimulation \"SG\" by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
            }, 
            {
                "arm_group_label": "Control group (CG)", 
                "arm_group_type": "Sham Comparator", 
                "description": "Control group \"CG\" will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
            }
        ], 
        "brief_summary": {
            "textblock": "Feeding intolerance is a common problem in preterm infants."
        }, 
        "brief_title": "Glycerin Suppositories for Treatment of Feeding Intolerance in Preterm Infants", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Feeding Intolerance", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Preterm infants with birth weight equal or less than 1500 g\n\n        Exclusion Criteria:\n\n          -  Significant congenital malformations\n\n          -  Severity of illness such that death is likely in the first few days after birth"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "230", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149407", 
            "org_study_id": "0752"
        }, 
        "intervention": [
            {
                "arm_group_label": "Glycerin group (GG)", 
                "description": "Glycerin group \"GG\" will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery.", 
                "intervention_name": "Glycerin", 
                "intervention_type": "Drug", 
                "other_name": "Glycerine"
            }, 
            {
                "arm_group_label": "Rectal stimulation group (SG)", 
                "description": "Rectal stimulation \"SG\" by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall.", 
                "intervention_name": "Rectal stimulation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Control group (CG)", 
                "description": "Control group \"CG\" will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes.", 
                "intervention_name": "Control", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glycerol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 25, 2014", 
        "location": [
            {
                "contact": {
                    "email": "latifa369@yahoo.com", 
                    "last_name": "Latifa Almahmoud"
                }, 
                "facility": {
                    "address": {
                        "city": "Riyadh", 
                        "country": "Saudi Arabia"
                    }, 
                    "name": "King Saud Medical City"
                }, 
                "investigator": [
                    {
                        "last_name": "latifa Almahmoud", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Haider Somaily", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nabeel Al-Odaisan", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sadia Al-Shehri", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jasim1800@yahoo.com", 
                    "last_name": "Jasim Anabrees, FRCPCH"
                }, 
                "facility": {
                    "address": {
                        "city": "Riyadh", 
                        "country": "Saudi Arabia"
                    }, 
                    "name": "Sulaiman Al Habib Medical Group"
                }, 
                "investigator": {
                    "last_name": "Jasim Anabrees, FRCPCH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Saudi Arabia"
        }, 
        "number_of_arms": "3", 
        "official_title": "Efficacy and Safety of Glycerin Suppositories for Treatment of Feeding Intolerance in Very Low Birth Weight Infants", 
        "other_outcome": [
            {
                "description": "Growth parameters at discharge from hospital include: Weight (grams), Length (cm), and Head circumference (cm)", 
                "measure": "Growth at discharge from hospital", 
                "safety_issue": "No", 
                "time_frame": "At discharge from hospital, an expected average of 8 weeks"
            }, 
            {
                "description": "Defined by the International Classification of Retinopathy of Prematurity (ICORP)", 
                "measure": "Retinopathy of prematurity (ROP)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 8 weeks"
            }, 
            {
                "measure": "Bronchopulmonary dysplasia (BPD)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 8 weeks"
            }, 
            {
                "description": "Diagnosed by echocardiogram", 
                "measure": "Patent ductus arteriosus (PDA)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 8 weeks"
            }, 
            {
                "description": "For example: Rectal bleeding, Rectal Perforation, or Hematochezia", 
                "measure": "Side effects", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 8 weeks"
            }
        ], 
        "overall_contact": {
            "email": "jasim1800@yahoo.com", 
            "last_name": "Jasim Anabrees"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Saudi Arabia: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Days to achieve full enteral feeding", 
            "measure": "Time to full feeding (days)", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149407"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Feeding intolerance defined as feeding withheld, discontinued, or decreased because the infant was not tolerating enteral feedings.", 
                "measure": "Incidence of feeding intolerance", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 4 weeks"
            }, 
            {
                "description": "Necrotizing enterocolitis (NEC) defined as per Bell's staging.", 
                "measure": "Incidence of necrotizing enterocolitis (NEC)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 8 weeks"
            }, 
            {
                "description": "Incidence of proven late onset infection defined as clinical signs in addition to positive blood culture beyond 72 hours of age.", 
                "measure": "Incidence of proven late onset infection", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 8 weeks"
            }, 
            {
                "description": "Incidence of hyperbilirubinemia defined as level of bilirubin requiring treatment with phototherapy according to the bilirubin chart used in the participating unit.", 
                "measure": "Incidence of hyperbilirubinemia", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 8 weeks"
            }, 
            {
                "measure": "Length of hospital stay (days)", 
                "safety_issue": "No", 
                "time_frame": "At discharge from hospital, an expected average of 8 weeks"
            }
        ], 
        "source": "King Saud Medical City", 
        "sponsors": {
            "collaborator": {
                "agency": "Sulaiman Al Habib Medical Group- Arrayan Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "King Saud Medical City", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}